Primary: To compare Event-free survival (EFS) per RECIST in subjects treated with pembrolizumab in combination with CRT and subjects treated with placebo in combination with CRT.Secondary:(1) To compare Overall Survival (OS) in subjects treated with…
ID
Source
Brief title
Condition
- Other condition
- Miscellaneous and site unspecified neoplasms malignant and unspecified
Synonym
Health condition
hoofd-hals tumoren
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Event free survival (EFS) by RECIST 1.1
Secondary outcome
Overall Survival (OS)
Safety and tolerability of pembrolizumab + CRT
Changes with regard to baseline of global health status / quality of life, and
swallowing, speech and pain symptoms, as measured by EORTC QLQ-C30 and
QLQ-H&N35
Background summary
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer
worldwide with around 600,000 new cases diagnosed per year. Around 50% of HNSCC
are diagnosed at a locally advanced stage. The survival rates for all subjects
with HNSCC are around 70% at 1 year and 40-60% at 5 years. The treatment choice
depends on the location of the primary tumor, the stage of the disease, and the
expected oncological and functional outcomes. Early stage HNSCC is usually
treated with single modality therapy, i.e., surgery or RT. The standard of care
for locally advanced HNSCC cancers not treated by surgery is concomitant CRT
with high-dose cisplatin. Meta-analysis of chemotherapy in combination with
radiation therapy (RT) for HNSCC showed that the addition of chemotherapy
concomitantly to RT improves the absolute 5-year survival by 6.5%. There is a
huge need to identify new treatment strategies that can increase the efficacy
of CRT. Preclinical studies suggesting the importance of immune priming would
support the notion that administering pembrolizumab prior to CRT may be
important. An initial phase IB Merck Investigator Studies Program (MISP) study
of pembrolizumab in combination with CRT for locally advanced HNSCC has been
initiated to evaluate the safety and tolerability of pembrolizumab combined
with cisplatin and RT. The preliminary results of the combination of
pembrolizumab with CRT in this MISP study supports further investigation into
the potential activity and safety of this treatment regimen.
Study objective
Primary:
To compare Event-free survival (EFS) per RECIST in subjects treated with
pembrolizumab in combination with CRT and subjects treated with placebo in
combination with CRT.
Secondary:
(1) To compare Overall Survival (OS) in subjects treated with pembrolizumab in
combination with CRT and subjects treated with placebo in combination with CRT.
(2) To evaluate and compare the safety and tolerability profile of
pembrolizumab in combination with CRT and subjects treated with placebo in
combination with CRT.
(3) To compare mean change from baseline in quality of life and physical
functioning, and swallowing, speech and pain symptoms in subjects treated with
pembrolizumab in combination with CRT and subjects treated with placebo in
combination with CRT.
Study design
This is a Phase III, randomized, placebo-controlled, double-blind study to
determine the efficacy and safety of pembrolizumab given concomitantly with
chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in
subjects with locally advanced head and neck squamous cell carcinoma (LA
HNSCC).
Intervention
Group 1:
Pembrolizumab 200 mg IV Q3W (up to 17 cycles) +
Cisplatin 100 mg/m2 IV Q3W (up to 3 cycles) +
Radiotherapy AFX (6 weeks) of SFX (7 weeks), 70Gy
Group 2:
Placebo (up to 17 cycles) +
Cisplatin 100 mg/m2 IV Q3W (up to 3 cycles) +
Radiotherapy AFX (6 weeks) of SFX (7 weeks), 70Gy
Study burden and risks
The patients will receive standard treatment for HNSCC during the first 8
weeks. Standard treatment consists of chemoradiation therapy. Intravenously
administered pembrolizumab or placebo will be added concomitantly. In this
phase, the patients will visit the clinic on a weekly basis.
After the first 8 weeks, the patients will receive either pembrolizumab or
placebo, intravenously, every three weeks, up to a maximum of 17 treatments in
total (approximately 1 year).
The standard treatment for this indication is quite invasive in itself. Many of
the procedures mentioned hereafter are part of the standard treatment as well.
The burden for the patient consists of;
- CT of head/neck or a CT of the chest + MRI of the head/neck, and FDG-PET or
FDG-PET/CT scan.
- Oral and dental exam, neurological exam, audiometric testing.
- If needed (if not done in six weeks prior to screening), a fiber-optic exam +
endoscopy with biopsy.
- A physical exam will be done during each study visit, and blood samples will
be collected.
- Neck-dissection (if indicated)
- Completion of questionnaires
The patient may experience physical or psychological discomfort during the
procedures taking place during the visits, such as blood collection, biopsy,
administration of IV line, ECG, CT/MRI/PET scan. The most common side effects
that have been reported with the use of MK3475 are fatigue, itching, decreased
appetite, shortness of breath, coughing.
Waarderweg 39
Haarlem 2031 BN
NL
Waarderweg 39
Haarlem 2031 BN
NL
Listed location countries
Age
Inclusion criteria
1. Have a pathologically proven new diagnosis of squamous cell carcinoma of:
a. Oropharyngeal p16 positive
b. Oropharyngeal p16 negative
c. Larynx/hypopharynx/oral cavity (independent of p16)
2. Be willing and able to provide written informed consent for the trial. The
subject may also provide consent for Future Biomedical Research. However, the
subject may participate in the main trial without participating in Future
Biomedical Research.
3. Have results from (local) testing of HPV status for oropharyngeal cancer. If
HPV status was previously tested using the method as prescribed by protocol, no
additional testing is required.
4. Have provided adequate tissue in terms of quality and quantity for PD-L1
biomarker analysis from a core or excisional biopsy. If an excisional or
incisional biopsy has been performed, subjects remain eligible for the study
provided the residual disease meets the staging criteria required for the trial
(e.g., excisional biopsy of a lymph node with residual T4 primary). Prior
surgical debulking, including tonsillectomy, for the head and neck cancer under
study is not allowed.
5. Be >=18 years of age on day of signing informed consent.
6. Have evaluable tumor burden (measurable and/or non-measurable tumor lesions)
assessed by CT scan or MRI, based on RECIST version 1.1.
7. Be eligible for definitive CRT and not considered for primary surgery based
on investigator decision.
8. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
0 or 1 performed within 10 days of treatment initiation.
9. Female subjects of childbearing potential must have a negative urine or
serum pregnancy test within 72 hours prior to receiving the first dose of trial
treatment. If the urine test is positive or cannot be confirmed as negative, a
serum pregnancy test will be required.
10. Female subjects of childbearing potential must be willing to use an
adequate method of contraception as outlined in the protocol, for the course of
the study through 180 days after the last dose of study medication.
11. Male subjects of childbearing potential must agree to use an adequate
method of contraception as outlined in the protocol, starting with the first
dose of study therapy through 180 days after the last dose of study therapy.
12. Demonstrate adequate organ function as defined in the protocol. All
screening labs should be performed within 10 days prior to treatment initiation
and assessed prior to randomizing the subject.
Exclusion criteria
1. Has current participation or treatment with an investigational agent or use
of an investigational device within 4 weeks of the first dose of trial
treatment.
2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent
or with an agent directed to another co-inhibitory T-cell receptor or has
previously participated in Merck MK-3475 clinical trials.
3. Has received a live vaccine within 30 days prior to the first dose of study
treatment.
4. Has cancer outside of the oropharynx, larynx, and hypopharynx or oral
cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown
primary HNC.
5. Has had prior systemic therapy, targeted therapy, radiotherapy treatment or
radical surgery for head and neck cancer under study.
6. Has Grade >=2 audiometric hearing loss. Audiometric abnormalities without
corresponding clinical symptoms of Grade >=2 hearing loss will not be grounds
for exclusion.
7. Has Grade >=2 neuropathy.
8. Has Grade 3-4 bleeding due to the underlying malignancy.
9. If subject has received major surgery, and the subject has not recovered
adequately form the toxicity and/or complications from the intervention prior
to starting trial treatment.
10. Has known active Hepatitis B or C.
11. Has known history of Human Immunodeficiency Virus (HIV) (HIV-1/2
antibodies).
12. Has a diagnosis of immunodeficiency or is receiving systemic steroid
therapy or any other form of immunosuppressive therapy within 7 days prior to
the first dose of trial treatment. Corticosteroid use as pre-medication for
allergic reactions (e.g. IV contrast), or as a prophylactic management of
adverse events related to the chemotherapies specified in the protocol is
allowed. A short course of steroids may be used as concomitant medication for
either treatment of an adverse event or medical condition with Sponsor approval.
The use of physiologic doses of corticosteroids may be approved after
consultation with the Sponsor.
13. Has a history of (non-infectious) pneumonitis that required steroids or
current pneumonitis.
14. Has an active autoimmune disease that has required systemic treatment in
the past 2 years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment.
15. Has history of a diagnosed and/or treated hematologic or primary solid
tumor malignancy, unless in remission for at least 5 years prior to
randomization. A T1-2 prostatic cancer Gleason score <=6, superficial bladder
cancer, non melanomatous skin cancer or carcinoma in situ of the cervix is
eligible. Other exceptions may be considered with Sponsor consultation.
16. Has known active central nervous system (CNS) metastases and/or
carcinomatous meningitis.
17. Has had previous allogeneic tissue/solid organ transplant.
18. Has active infection requiring systemic therapy.
19. Has a history of severe hypersensitivity reaction (e.g., generalized
rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to
pembrolizumab, cisplatin or radiotherapy or their analogs.
20. Is a female subject who is pregnant or breast feeding or a male expecting
to conceive or father children within the projected treatment phase of the
trial, starting with the screening visit through 180 days after the last dose
of trial treatment.
21. Have severe comorbidities that, in the opinion of the Investigator, might
hamper participation in the study and/or the treatment administration.
22. Has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the trial, interfere with the
subject*s participation for the full duration of the trial, or is not in the
best interest of the subject to participate, in the opinion of the treating
investigator.
23. Has known psychiatric or substance abuse disorders that would interfere
with cooperation with the requirements of the trial.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2016-003934-25-NL |
CCMO | NL60000.056.16 |